Read More Pharma Industry News Can oral NMDA blockers like Ketamir-2 disrupt current off-label CIPN treatments? Find out how MIRA Pharmaceuticals’ Ketamir-2 aims to disrupt CIPN care with oral NMDA therapy as the company targets Fast Track and prepares for Phase 2a trials. bySoujanya RaviFebruary 6, 2026